{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:30:23Z","timestamp":1785879023328,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10096-020-04118-w","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T05:03:07Z","timestamp":1609995787000},"page":"1191-1198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to Pneumocystis pneumonia"],"prefix":"10.1007","volume":"40","author":[{"given":"Gaston","family":"Burghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Biard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Valade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Robert-Gangneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Hamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00e9le","family":"Maubon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Debourgogne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e9ne","family":"Le Gal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9deric","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Leterrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Toubas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Pomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Pauline","family":"Bellanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bonhomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Iriart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durand-Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Magne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Maury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Lemiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"4118_CR1","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1378\/chest.07-0223","volume":"132","author":"G Boll\u00e9e","year":"2007","unstructured":"Boll\u00e9e G, Sarfati C, Thi\u00e9ry G, Bergeron A, de Miranda S, Menotti J et al (2007) Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest 132:1305\u20131310","journal-title":"Chest"},{"key":"4118_CR2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/ijd.13231","volume":"55","author":"TM Gonzalez Santiago","year":"2016","unstructured":"Gonzalez Santiago TM, Wetter DA, Kalaaji AN, Limper AH, Lehman JS (2016) Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis. Int J Dermatol 55:823\u2013830","journal-title":"Int J Dermatol"},{"key":"4118_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/23744235.2018.1558368","volume":"51","author":"T Matsumoto","year":"2019","unstructured":"Matsumoto T, Fujita M, Hirano R, Sasaki T, Watanabe K (2019) Risk factors for pneumocystis pneumonia onset in HIV-negative patients treated with high-dose systemic corticosteroids. Infect Dis (Lond) 51:305\u2013307","journal-title":"Infect Dis (Lond)"},{"issue":"2","key":"4118_CR4","doi-asserted-by":"publisher","first-page":"e13245","DOI":"10.1111\/tid.13245","volume":"22","author":"SY Park","year":"2020","unstructured":"Park SY, Jung JH, Kwon H, Shin S, Kim YH, Chong Y et al (2020) Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: a case-control study. Transpl Infect Dis 22(2):e13245","journal-title":"Transpl Infect Dis"},{"key":"4118_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2169\/internalmedicine.3907-19","volume":"59","author":"H Watanabe","year":"2020","unstructured":"Watanabe H, Kitahara Y, Murakami Y, Nihashi F, Matsushima S, Eifuku T et al (2020) Pneumocystis jirovecii pneumonia in a patient with breast cancer receiving neoadjuvant dose-dense chemotherapy. Intern Med 59:987\u2013990","journal-title":"Intern Med"},{"key":"4118_CR6","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3201\/eid2009.131668","volume":"20","author":"A Roux","year":"2014","unstructured":"Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A et al (2014)Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 20:1490\u20131497","journal-title":"Emerg Infect Dis"},{"key":"4118_CR7","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/cc6806","volume":"12","author":"X Monnet","year":"2008","unstructured":"Monnet X, Vidal-Petiot E, Osman D, Hamzaoui O, Durrbach A, Goujard C et al (2008) Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care 12:R28","journal-title":"Crit Care"},{"key":"4118_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1378\/chest.128.2.573","volume":"128","author":"E Festic","year":"2005","unstructured":"Festic E, Gajic O, Limper AH, Aksamit TR (2005) Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 128:573\u2013579","journal-title":"Chest"},{"key":"4118_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00262-010-0920-3","volume":"60","author":"FJ Gassner","year":"2011","unstructured":"Gassner FJ, Weiss L, Geisberger R, Hofbauer JP, Egle A, Hartmann TN et al (2011) Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. Cancer Immunol Immunother 60:75\u201385","journal-title":"Cancer Immunol Immunother"},{"key":"4118_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrmicro1621","volume":"5","author":"CF Thomas","year":"2007","unstructured":"Thomas CF, Limper AH (2007) Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 5:298\u2013308","journal-title":"Nat Rev Microbiol"},{"key":"4118_CR11","doi-asserted-by":"publisher","first-page":"e12876","DOI":"10.1111\/tid.12876","volume":"20","author":"WA Werbel","year":"2018","unstructured":"Werbel WA, Ison MG, Angarone MP, Yang A, Stosor V (2018) Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation. Transpl Infect Dis 20:e12876","journal-title":"Transpl Infect Dis"},{"key":"4118_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1179\/joc.2006.18.4.339","volume":"18","author":"L Pagano","year":"2006","unstructured":"Pagano L, Fianchi L, Leone G (2006) Fungal pneumonia due to molds in patients with hematological malignancies. J Chemother 18:339\u2013352","journal-title":"J Chemother"},{"key":"4118_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s10156-012-0453-0","volume":"18","author":"S Tasaka","year":"2012","unstructured":"Tasaka S, Tokuda H (2012) Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother 18:793\u2013806","journal-title":"J Infect Chemother"},{"key":"4118_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13613-019-0604-x","volume":"9","author":"BJ Gaborit","year":"2019","unstructured":"Gaborit BJ, Tessoulin B, Lavergne R-A, Morio F, Sagan C, Canet E et al (2019) Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study. Ann Intensive Care 9:131","journal-title":"Ann Intensive Care"},{"key":"4118_CR15","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMra032588","volume":"350","author":"CF Thomas","year":"2004","unstructured":"Thomas CF, Limper AH (2004) Pneumocystis pneumonia. N Engl J Med 350:2487\u20132498","journal-title":"N Engl J Med"},{"issue":"3","key":"4118_CR16","doi-asserted-by":"publisher","first-page":"e00939","DOI":"10.1128\/IAI.00939-16","volume":"85","author":"V Nandakumar","year":"2017","unstructured":"Nandakumar V, Hebrink D, Jenson P, Kottom T, Limper AH (2017) Differential macrophage polarization from Pneumocystis in immunocompetent and immunosuppressed hosts: potential adjunctive therapy during pneumonia. Infect Immun 85(3):e00939-16","journal-title":"Infect Immun"},{"key":"4118_CR17","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1128\/AAC.00669-11","volume":"55","author":"SM Moon","year":"2011","unstructured":"Moon SM, Kim T, Sung H, Kim M-N, Kim S-H, Choi S-H et al (2011) Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 55:4613\u20134618","journal-title":"Antimicrob Agents Chemother"},{"key":"4118_CR18","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.chest.2018.04.026","volume":"154","author":"PM Wieruszewski","year":"2018","unstructured":"Wieruszewski PM, Barreto JN, Frazee E, Daniels CE, Tosh PK, Dierkhising RA et al (2018) Early corticosteroids for Pneumocystis pneumonia in adults without HIV are not associated with better outcome. Chest 154:636\u2013644","journal-title":"Chest"},{"key":"4118_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jcrc.2020.01.027","volume":"57","author":"E Borcoman","year":"2020","unstructured":"Borcoman E, Dupont A, Mariotte E, Doucet L, Joseph A, Chermak A et al (2020) One-year survival in patients with solid tumours discharged alive from the intensive care unit after unplanned admission: a retrospective study. J Crit Care 57:36\u201341","journal-title":"J Crit Care"},{"key":"4118_CR20","doi-asserted-by":"publisher","first-page":"e13587","DOI":"10.1111\/ctr.13587","volume":"33","author":"JA Fishman","year":"2019","unstructured":"Fishman JA, Gans H (2019) AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl 33:e13587","journal-title":"Clin Transpl"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-020-04118-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-020-04118-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-020-04118-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T14:17:19Z","timestamp":1621606639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-020-04118-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["4118"],"URL":"https:\/\/doi.org\/10.1007\/s10096-020-04118-w","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"22 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The appropriate ethics committee approved the first study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Non-applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Non-applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"It was not required because of observational study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Antoine Roux, MD,; Sandrine Valade, MD; Florence Gangneux-Robert, PharmD, PhD; Samia Hamane, MD; Daniele Maubon, MD, PhD; Anne Debourgogne, PhD, MPH; Sol\u00e8ne Le Gal, DVM, PhD; Frederic Dalle, PharmD, PhD; Marion Leterrier, PharmD; Dominique Toubas, MD, PhD; Christelle Pomares, MD, PhD; Anne Pauline Bellanger, PharmD, PhD; Julie Bonhomme, MD, PhD; Xavier Iriart, PhD; Isabelle Durand-Joly, PhD; Denis Magne, PhD; Denis Pons, Pharmacien Biologiste; and Eric Maury, MD, PhD, have disclosed no relevant financial relationships. Christophe Hennequin, MD, PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Gilead Sciences, Inc., Merck Sharp & Dohme Corp; Pfizer Inc. Elie Azoulay, MD, PhD, has disclosed the following relevant financial relationships: Gilead Sciences, Pfizer, Astellas, Alexion, Fisher-Paykel. Dr. Lemiale has disclosed being memeber of a research group which received grant from Pfizer, Fisher-Paykel, Gilead, Alexion, Astellas.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}